Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × matuzumab × Clear all
NCT00215644 2018-11-02

MATRIX EG

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
72 enrolled 7 charts
Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT00111839 2018-04-06

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

EMD Serono

Phase 2 Completed
150 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00073541 2017-01-20

A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer

EMD Serono

Phase 2 Completed
38 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡